Table 2. ADCEPI, ADCHASTE, ΔSUVmean and ΔSUVmax for primary tumors at baseline and early during treatment.
No. of patient | Primary tumor |
|||||
---|---|---|---|---|---|---|
ADCEPI MRI1 (×10–5 mm2/s) | ADCEPI MRI2 (×10–5 mm2/s) | ADCHASTE MRI1 (×10–5 mm2/s) | ADCHASTE MRI2 (×10–5 mm2/s) | ΔSUVmean PET1-2 (%) | ΔSUVmax PET1-2 (%) | |
1 | 84 | 117 | 114 | 111 | 15.9 | 15.8 |
2 | 85 | 102 | 106 | 128 | NA1 | NA1 |
3 | 104 | 134 | 70 | 73 | NA2 | NA2 |
4 | 77 | 143 | 58 | 73 | –74.5 | –79.5 |
5 | NA3 | NA3 | NA3 | NA3 | NA3 | NA3 |
6 | 56 | 57 | 85 | 74 | –69.1 | –69.4 |
7 | 77 | 98 | 74 | 54 | –54.4 | –54.9 |
8 | 66 | 113 | 65 | 78 | NA4 | NA4 |
1, PET1 was performed without a transmission scan; 2, PET1 was reconstructed with an aberrant voxel size; 3, no primary tumor; 4, PET2 was not performed; NA, not applicable.